Superiority of single-donor apheresis platelets (SDAP) over pooled platelet concentrates (PPC) transfusions is largely assumed, but unproven. We hypothesized that prophylactic SDAP and PPC transfusions are clinically equivalent after allogeneic hematopoietic stem cell transplants (HSCT). We studied all transfusions administered to 33 patients with AML/MDS during the first 100 days after busulfan-based, myeloablative HSCT. All donorrecipient pairs were ABO identical. Transfusion threshold was a platelet count p15 Â 10 9 /l. The corrected increment (CCI) was used for all comparisons. Median time to platelet engraftment was 13 days (n ¼ 30). PPC transfusions (n ¼ 105) were ABO compatible, while 10% of 41 SDAP were not (P ¼ 0.006). Median post-transfusion platelet count was 51K/ll (5-118K) after SDAP and 36K/ll (3-115K) after PPC (P ¼ 0.0004). Median CCI was 14.178 (SDAP) versus 7.793 (PPC) (P ¼ 0.0001). Median time to another transfusion was 3 days (SDAP) and 2 days (PPC; P ¼ 0.3). In the week following any given transfusion, the median number of new transfusions was similar (n ¼ 2), as well as the need of further transfusion (16 versus 24%, P ¼ 0.2). A total of 17% of SDAP and 30% of PPC transfusions were labeled 'ineffective' (P ¼ 0.1). There were two non-lethal hemorrhage episodes (6%). SDAP transfusions produced better platelet counts, but SDAP and PPC were equally effective in preventing hemorrhage.
Introduction
Platelet transfusion refractoriness is a frequent problem for multitransfused patients. 1 In the context of acute myeloid leukemia (AML), refractoriness rates of up to 27% have been reported. 2 Contributing causes include alloimmunization, 3, 4 splenomegaly, fever, frequent infections and use of amphotericin. 5, 6 In the setting of allogeneic hematopoietic stem cell transplantation (HSCT), platelet transfusion refractoriness can be a dramatic situation, 7 given the occurrence of other risk factors for bleeding such as graft-versus-host disease, infections, sepsis, organ dysfunction and disseminated intravascular coagulation. 8 Several strategies have been added to transfusional practice, in an attempt to minimize the problem: leukoreduction, 9 use of ultraviolet irradiated products, 10 dosedependent platelet transfusion trials, 11 use of ABOidentical platelet concentrates, 12 HLA-matched platelet transfusions 13 and use of single-donor apheresis platelets (SDAP) products. The use of SDAP or higher doses of platelets is still controversial and associated with higher costs. 14, 15 Some authors advocate the use of SDAP due to less exposure to multiple donors, resulting in smaller risk of contamination with infectious diseases and lower risk of developing alloantibodies. 16, 17 However, it is unclear if using SDAP improves outcomes of transfusions, as opposed to using the more readily available pooled platelet concentrates (PPC).
Here, we report a retrospective comparison of performance of SDAP versus PPC transfusions when used prophylactically in the context of allogeneic HSCT. In order to minimize heterogeneity and the effect of multiple variables likely operating in this complex scenario, we selected patients that received allogeneic transplants from ABO-identical donors. Furthermore, all patients received intravenous busulfan-based myeloablative preparative regimens to treat AML or high-risk myelodysplastic syndrome (MDS). 2 given at transplant days þ 1, þ 3, þ 6 and þ 11. Recipients of matched unrelated donor or one-mismatchrelated donor transplants received antithymocyte globulin additionally. Alloimmunization for RBC antigens was identified in three patients before transplant.
Materials and methods

Patients
Platelet engraftment was defined as the first of seven consecutive days with a platelet count 420 Â 10 9 /l without transfusions, and neutrophil engraftment as the first of three consecutive days with an absolute neutrophil count4500 /ml.
Platelet transfusions
PPC were obtained from units of whole blood collected according to current standards of the food and drug administration (FDA) and American association of blood banks (AABB). Platelet concentrates used for transfusions were less than 36 h old and contained an average of 0.85-1.10 Â 10 11 platelets per unit. Each transfusion request was adjusted to the body weight of the patient. SDAP were produced by standard methods of apheresis, according to standards and requirements of the FDA and recommendations of the AABB. All SDAP were transfused the following day of collection, usually in less than 24 h. SDAP units were not split and contained a minimum of six PPC unit equivalents (4-6 Â 10 11 platelets/concentrate). All transfusions were leukoreduced and irradiated with a Cs137 source, before release for transfusion. The leukoreduction of the random donor platelets was performed at the bedside. The apheresis platelets were leukoreduced, at the bedside, if the white cell contamination, as determined by flow cytometry, was higher that 1 Â 10 6 . In all cases the Sepacell PLA-10A leukoreduction filter (Fenwall Division, Baxter Healthcare Corporation, Deerfield, IL, USA) was used.
Prophylactic transfusions were evaluated individually, and the two types of products were compared in regards to platelet count increment, effective prevention of bleeding and number of days to the next transfusion, during the first 100 days post-transplantation. The majority of patients received in some point of their post-transplant course both types of platelet products, depending on availability at the blood bank. Transfusions administered in the setting of bleeding were excluded from this analysis. According to institutional guidelines, prophylactic platelet transfusions were administered for platelet count of 15 Â 10 9 /l or below. PPC and SDAP were ABO identical when possible, but not as a rule. All transfusions received during the first 100 days after transplantation were analyzed.
Transfusion effectiveness evaluation
The corrected increment (CCI) was calculated for each transfusion according to standard formula. 18 PPC and SDAP were separated in groups, according to the sample collection time -1 h after the transfusion, 1 to less than 18 h and 18-24 h. The following cut-offs were used to classify the transfusions as refractory: 5.5 for the first-hour sample, 5.0 for the group collected between 1 and 18 h and 4.5 for the group collected with 18 h or later. 19 We evaluated the number of products that each patient had been exposed to before each platelet transfusion, and also
Results
Thirty-three patients fulfilled the inclusion criteria. Sixteen were males (49%) and 17 females, with a median age of 47 years (range, 22-66). They had received a median of 4 (range 1-13) chemotherapy cycles before transplant; diagnosis at transplant was AML for 24 (73%) and MDS for nine (27%) patients. Twelve (36%) patients were in first (n ¼ 4) or second (n ¼ 8) remission at transplant, and four patients were untreated ( Table 1) . Sources of stem cells were peripheral blood (n ¼ 23; 70%) and bone marrow (n ¼ 10; 30%). Twenty-six patients (79%) had a sibling donor; two had one antigen-mismatched donor and 24 were fully matched. Five patients received matched unrelated grafts and two had related donors other than siblings. Before HSCT, our 33 patients had received a median of 5 (range, 0-57) platelet transfusions (PPC or SDAP), and a median of 8 (range, 0-49) red blood cell transfusions.
Thirty-two patients had neutrophil recovery at a median of 12 days (range, 11-26). One patient had primary engraftment failure, and received a second transplant. Platelet engraftment was achieved by 30 patients at a median of 13 days (range, 8-51). Three patients failed to recover platelets: one had primary engraftment failure, and two patients died early.
The median follow-up for the group was 300 days (range, 24-720). During this period, 13 patients died; estimated median survival was 21 months. No death was secondary to a hemorrhagic episode. During the first 100 days of followup, two patients (6%) had bleeding episodes: one gastrointestinal and one hemorrhagic cystitis. Neither required red blood cell transfusion.
The 33 patients received 41 SDAP and 105 PPC transfusions during the first 100 days post-transplant. All PPC transfusions were ABO identical, while four (9.8%) had a different ABO type (P ¼ 0.006). Patients received a median of six PPC units (1 U/10 kg of body weight; range, [4] [5] [6] [7] [8] [9] [10] [11] [12] . Median platelet and hemoglobin levels before transfusion were similar for SDAP and PPC: platelets 14 000/ml (range, 6000-38 000) for SDAP and 15 000/ml for PPC (range, 5000-47 000), and hemoglobin 8.6 g/dl (range, 7.5-11.0) for SDAP versus 8.9 g/dl (range, 7.2-13.2) (P ¼ NS for both comparisons). The median post-transfusion platelet count was 51 000/ml (range, 5000-118 000) for SDAP and 36 000/ml (range, 3000-115 000) for PPC (P ¼ 0.0004). The median CCI was 14.178 for SDP and 7.793 for the PPC (P ¼ 0.0001), both above the level to consider a transfusion as 'refractory' (Table 2) . Seven out of 41 SDAP (17.1%) transfusions resulted in an ineffective CCI, versus 32 out of 105 PPC (30.4%) (P ¼ 0.1).
Fever was seen on the same day for six SDAP (15%) and 14 PPC (13%) transfusions. Amphotericin was administered on the same day for three SDAP (7.3%) versus 14 PPC (13.3%), while vancomycin was administered for 12 SDAP (29.3%) and 38 PPC (36.2%) transfusions (P ¼ NS for all comparisons).
After an SDAP transfusion, it took a median of 3 days (range, 0-10) until another transfusion was administered; this median interval was 2 days (range, 0-10) after PPC products (P ¼ 0.3). The median number of new transfusions needed in the following week was similar for both groups (n ¼ 2; range, 0-7). Twenty-four percent of the SDAP transfusions resulted in no need for platelet supplementation in the following week, versus 16% of the PPC (P ¼ 0.2). Seventeen percent of the SDAP transfusions were labeled refractory, as compared to 30% of the PPC (P ¼ 0.1).
Discussion
We were unable to detect any clinical relevant difference between SDAP and PPC transfusions when used as bleeding prophylaxis after allogeneic HSCT. SDAP provided better post-transfusion platelet counts and CCI, but this did not translate into clinically important parameters.
In contrast to our results, Slichter et al. 2 reported superiority of SDAP over PPC for AML patients receiving induction chemotherapy. That analysis, however, did not involve recipients of allogeneic transplants, which in general are heavily exposed to blood products by the time they are transplanted. Interestingly, there have been very few attempts to compare sources of platelets for transfusion in the allogeneic HSCT setting. Prophylactic platelet transfusions in allogeneic HSCT E Gurkan et al Our analysis is limited by its retrospective nature and the lack of a cohort of patients that received only either SDAP or PPC products. As a retrospective study, based on the available sample size, it was not designed to 'demonstrate equivalence', instead to evaluate clinical efficacy of both types of products in preventing hemorrhage. However, such a prospective, randomized comparison is unlikely to be performed in this particular context of allogeneic hematopoietic transplant, given the logistics involved. We tried to minimize these biases by studying a homogeneous group of patients, with the same diagnosis, with ABO-identical donors, treated with busulfan-based conditioning regimens.
PPC transfusions are less demanding in logistic terms and are likely to decrease the economic burden of blood products in the transplant process. 20, 21 Our analysis would indicate that in the context of allogeneic HSCT, PPC are as clinically effective as SDAP.
